Market Cap
$126.4M
NRXP
NRX Pharmaceuticals, Inc.
$2.90 ▲ +1.93%
Prev close $2.85Market cap$126.4M
ConsensusStrong Buy
12-mo target$38.50 (+1225.3%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)8 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on NRXP right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (91%)
Inst. Holders
36 funds
Inst. Value
$28.6M
Inst. Activity
8 buys / 0 sells
Social Sentiment
72° Bullish
SEC Reports
9
Press Releases
7
Price chart 30d -15.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Nov 10, 2026 fda_pdufa
Sep 16, 2026 SEC PDUFA: NRXP — NRX-100 in drug shortage product — 2026-11-10
FDA target action date 2026-11-10 for NRXP (NRX Pharmaceuticals, Inc.). Drug: NRX-100. Indication: d
NRx Pharmaceuticals announced that the FDA reclassified its ANDA amendment for preservative-free ketamine (NRX-100) from
8-K — Impact 5/10
NRX Pharmaceuticals filed an 8-K furnishing an investor presentation used in meetings with investors and analysts on Sep
8-K — Impact 2/10
NRx Pharmaceuticals reported Q2 2026 financial results with a net loss of $18.0M for the six months ended June 30, 2026,
8-K — Impact 7/10
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
1,618,159 shares ($6.6M)
Jun 30, 2026 Inst.
Jun 22, 2026 Press UBS Group AG — DOUBLED
423,115 shares ($1.7M)
NRx Pharmaceuticals announced FDA approval of an Expanded Access Protocol for NRX-101 (D-cycloserine/lurasidone) to augm
Impact 4/10
NRx Pharmaceuticals announced the presentation of a peer-reviewed poster at the 2026 ASCP conference showing that IV ket
Impact 7/10
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
91% rate it Buy or better · 11 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 1, 2026 | Ascendiant Capital | MAINTAIN | Buy | 40% |
| Sep 14, 2026 | BTIG | REITERATE | Buy | 53% |
| Aug 25, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 18, 2026 | BTIG | REITERATE | Buy | 53% |
| Aug 7, 2026 | BTIG | MAINTAIN | Buy | 53% |
| May 5, 2026 | D. Boral Capital | MAINTAIN | Buy | 33% |
| Apr 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Apr 27, 2026 | Ascendiant Capital | MAINTAIN | Buy | 40% |
| Apr 23, 2026 | D. Boral Capital | MAINTAIN | Buy | 33% |
| Apr 20, 2026 | D. Boral Capital | MAINTAIN | Buy | 33% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Aug 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Jul 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Jun 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% |
Price targets
Where 4 covering analysts think NRXP trades over the next 12 months.
$38.50 +1225.3% upside Strong Buy
Current$2.91 Low$10.00 Median$47.00 High$50.00 4 analysts
$10.00$50.00
Analyst rating Strong Buy· 1.0/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
72°
Bullish
BearishNeutralBullish
Recent posts
NRx Pharmaceuticals (NRXP) - Outstanding DARPA-funding PR published this morning PLUS status update to September Catalysts post from a month ago. The positive catalysts are mounting!
▲ 1 · 💬 1· ⚡ 0.5
New to trading
▲ 1 · 💬 5· ⚡ 0.5
NRx Pharmaceuticals (NRXP) - Two September Catalysts Upon Us
▲ 1 · 💬 1· ⚡ 0.5
The important "rest of the story" you need to know regarding NRx Pharmaceuticals (NRXP) and the anticipated upcoming ANDA approval for no-preservative IV ketamine
▲ 1 · 💬 1· ⚡ 0.5
NRx Pharmaceuticals (NRXP) - Awaiting ANDA (generic drug) approval for no-preservative Intravenous (IV) ketamine for analgesia (pain control) and anesthesia ... which will happen in the near term.
▲ 1 · 💬 1· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 6 bullish, 0 bearish, 0 mixed, 3 neutral · avg impact 4.8/10.Plus 7 press releases.
BULLISH8-K5/10
NRx Pharmaceuticals announced that the FDA reclassified its ANDA amendment for preservative-free ket
Sep 16, 2026
NEUTRAL8-K2/10
NRX Pharmaceuticals filed an 8-K furnishing an investor presentation used in meetings with investors
Sep 14, 2026
BULLISH8-K7/10
NRx Pharmaceuticals reported Q2 2026 financial results with a net loss of $18.0M for the six months
Aug 17, 2026
BULLISHPRESS-RELEASE6/10
NRx Pharmaceuticals reported Q2 2026 EPS of -$0.04, beating consensus of -$0.08 by 50%, though reven
Aug 17, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Nov 10, 2026
fda_pdufa
PDUFA: NRXP — NRX-100 in drug shortage product — 2026-11-10
FDA target action date 2026-11-10 for NRXP (NRX Pharmaceuticals, Inc.). Drug: NRX-100. Indication: drug shortage product. GDUFA goal date revised to N
Sep 15, 2026
other
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
WILMINGTON, Del., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clini
Sep 11, 2026
other
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clini
Sep 8, 2026
other
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
WILMINGTON, Del., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-sta
Aug 26, 2026
short_volume
Short Volume: NRXP — 62.3% short (0.4M / 0.6M)
Short: 353,019 | Exempt: 0 | TRF Vol: 566,486 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.15 | $-0.15–$-0.15 | 70.4% | -87.5% | 0↑ 1↓ | $0.0B | 1 |
| Next Q | $-0.17 | $-0.17–$-0.17 | -192.7% | -466.7% | 0↑ 1↓ | $0.0B | 1 |
| Current FY | $-0.80 | $-0.80–$-0.80 | 40.3% | -122.2% | 0↑ 1↓ | $0.0B | 1 |
| Next FY | $-0.35 | $-0.35–$-0.35 | 56.3% | -170.0% | — | $0.1B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.150 | — |
| 7d ago | $-0.080 | -0.070 |
| 30d ago | $-0.080 | -0.070 |
| 60d ago | $-0.080 | -0.070 |
| 90d ago | $-0.080 | -0.070 |
Institutional ownership
Which big funds own NRXP (from quarterly 13F filings) and who is adding or trimming.
36 institutional holders with $28.6M total value (7,105,135 shares) as of 2026-Q2. Top holders: VANGUARD, AMERIPRISE, BALYASNY. Net buying activity: 8 institutions added/increased vs 0 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 1,618,159 | $6.6M | 23.1% | ADD +39.5% |
| AMERIPRISE FINANCIAL INC | 928,728 | $3.8M | 13.3% | — |
| BALYASNY ASSET MANAGEMENT L.P. | 893,864 | $3.7M | 12.8% | — |
| CITADEL ADVISORS LLC | 680,043 | $2.8M | 9.7% | — |
| COMMONWEALTH EQUITY SERVICES, LLC | 454,418 | $1.9M | 6.5% | — |
| UBS Group AG | 423,115 | $1.7M | 6.0% | DOUBLED +1577.2% |
| GEODE CAPITAL MANAGEMENT, LLC | 314,659 | $1.3M | 4.5% | ADD +41.7% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 226,800 | $927.6K | 3.2% | — |
| CITADEL ADVISORS LLC | 224,200 | $917.0K | 3.2% | — |
| BlackRock, Inc. | 220,460 | $901.7K | 3.1% | DOUBLED +122.7% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | 1,160,184 | 1,618,159 | +39.5% | $6.6M |
| UBS Group AG | DOUBLED | 25,227 | 423,115 | +1577.2% | $1.7M |
| BlackRock, Inc. | DOUBLED | 98,995 | 220,460 | +122.7% | $901.7K |
| JANE STREET GROUP, LLC | DOUBLED | 44,152 | 119,018 | +169.6% | $486.8K |
| STATE STREET CORP | ADD | 86,984 | 116,084 | +33.5% | $474.8K |
| NORTHERN TRUST CORP | ADD | 43,469 | 62,951 | +44.8% | $257.5K |
| MORGAN STANLEY | DOUBLED | 10,028 | 40,901 | +307.9% | $167.3K |
| OSAIC HOLDINGS, INC. | DOUBLED | 90 | 600 | +566.7% | $2.5K |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | 218,866 | 310,112 | +41.7% | $660.6K |
| NORTHERN TRUST CORP | ADD | 28,947 | 43,469 | +50.2% | $92.6K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
1 insiders, 1 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 27, 2026 | Casper Joseph Michael | Chief Operating Officer | AWARD | 100,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NRXP.
Shares short
9,773,562
Settlement Sep 15, 2026
Change vs prior
+5.1%
Semi-monthly cycle
Days to cover
16.3
At avg daily volume
Of shares outstanding
≈22.6%
Estimate — not % of float
All NRXP filing & press-release reports (16)
- 8-K reportSep 16, 2026
- 8-K reportSep 14, 2026
- 8-K reportAug 17, 2026
- PRESS-RELEASE reportAug 17, 2026
- 8-K reportAug 7, 2026
- 8-K reportJul 22, 2026
- PRESS-RELEASE reportJun 22, 2026
- PRESS-RELEASE reportJun 5, 2026
- PRESS-RELEASE reportJun 4, 2026
- PRESS-RELEASE reportJun 3, 2026
- PRESS-RELEASE reportJun 2, 2026
- PRESS-RELEASE reportMay 18, 2026
- PRESS-RELEASE reportMay 14, 2026
- PRESS-RELEASE reportMar 30, 2026
- PRESS-RELEASE reportMar 19, 2026
- DEFA14A reportFeb 24, 2026